Loading...

Statins and Ezetimibe Modulate Plasma Proprotein Convertase Subtilisin Kexin-9 (PCSK9) Levels

PCSK9 is a natural inhibitor of the LDL receptor. Gain-of-function mutations may cause the familial hypercholesterolemia phenotype, whereas loss-of-function variants associate with reduced LDL-C levels and lower coronary risk. Statins up-regulate PCSK9 in hepatocytes. We developed an assay to measur...

Full description

Saved in:
Bibliographic Details
Main Authors: Davignon, Jean, Dubuc, Geneviève
Format: Artigo
Language:Inglês
Published: American Clinical and Climatological Association 2009
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2744528/
https://ncbi.nlm.nih.gov/pubmed/19768174
Tags: Add Tag
No Tags, Be the first to tag this record!